Hadean Ventures

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Alex Health AB, based in Stockholm, is an innovative startup focused on integrating artificial intelligence and psychology to develop a second-generation behavioral change application. Founded in 2017, the company aims to assist one billion individuals in overcoming unhealthy habits to improve their mental health. Alex Therapeutics, its digital therapeutics arm, leverages a proprietary AI platform to create CE-marked software medical devices, offering evidence-based digital interventions across various therapeutic areas, including obesity, breast cancer, and nicotine addiction. By combining psychology, design, and technology, Alex Health seeks to democratize healthcare and provide personalized self-healthcare solutions through its digital applications. The company recently secured funding from the founders of Candy Crush, further supporting its mission to transform patient care and support clinicians in fostering healthier behaviors.

TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Ribbon Biolabs GmbH builds and develops synthesis of long deoxyribonucleic acid (DNA) molecule. It creates and explores genetic solutions by the throughput synthesis of DNA of unprecedented length. The company was founded in 2018 and is based in Vienna, Austria.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.

SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.

Oncoinvent AS is a Norwegian company focused on developing innovative cancer therapies. Founded in 2010 and headquartered in Oslo, the company specializes in antibody-based therapeutics, notably Radspherin, an alpha-emitting radioactive microsphere aimed at treating metastatic cancers within body cavities. Oncoinvent applies established physical and chemical principles with novel materials to enhance medical benefits while reducing potential safety risks. Its mission is to provide effective treatment options for cancer patients through advanced pharmaceutical products that integrate cutting-edge technology and research.

Step Pharma, founded in 2014 and based in Paris, France, is a biopharmaceutical company specializing in the development of novel small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. A spin-off of the Imagine Institute, Step Pharma emerged from research led by Professor Alain Fischer on genetic immunodeficiencies. The company collaborates with Sygnature Discovery, a prominent drug discovery services provider, and Kurma Partners, an investor focused on healthcare and biotechnology in Europe. Its proprietary therapeutics utilize a unique class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and improving therapeutic outcomes for patients with autoimmune disorders.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

CardioMech AS is a Norwegian company founded in 2015 and based in Trondheim, specializing in the development of catheter-based technology for treating structural heart disease. The company focuses on providing a transcatheter alternative to traditional open-heart surgery for the placement of artificial chords in the mitral valve. This innovative approach allows for the treatment of severe symptomatic degenerative mitral regurgitation, which can occur due to conditions such as prolapse or flail. By enabling surgeons to perform these procedures without the need for chest incisions, cardiac arrest, or heart-lung bypass, CardioMech aims to expand therapeutic options for patients suffering from this serious heart condition.

Gesynta Pharma AB is a pharmaceutical company based in Solna, Sweden, focused on developing selective inhibitors of microsomal prostaglandin E synthase-1 (mPGES-1) to address chronic inflammatory conditions and related diseases. The company conducts research on the role of arachidonic acid and aims to create oral treatments for cardiovascular diseases and cancer. Its lead product, GS-248, is a highly potent mPGES-1 inhibitor that has entered clinical phase development. By targeting the pro-inflammatory enzyme mPGES-1, Gesynta Pharma seeks to provide safe and effective anti-inflammatory and pain-relieving pharmaceuticals to improve patient outcomes in various serious diseases. Founded in 2017, the company is committed to advancing innovative therapies in the field of inflammation.

Oncoinvent AS is a Norwegian company focused on developing innovative cancer therapies. Founded in 2010 and headquartered in Oslo, the company specializes in antibody-based therapeutics, notably Radspherin, an alpha-emitting radioactive microsphere aimed at treating metastatic cancers within body cavities. Oncoinvent applies established physical and chemical principles with novel materials to enhance medical benefits while reducing potential safety risks. Its mission is to provide effective treatment options for cancer patients through advanced pharmaceutical products that integrate cutting-edge technology and research.

Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.

Nisonic is a medical technology company that develops products that will allow physicians to diagnose and monitor increased intracranial pressure (ICP) in an easier and cost-effective way. Nisonic will offer an accurate non-invasive ICP monitoring system for emergency departments, EMC, intensive care and critical care units. Early detection of ICP and intervention are critical to lowering death and disability rates, but currently only invasive methods are available to monitor increased ICP. Invasive methods are associated with risk of bleeding and infections, are only available at larger hospitals and have a considerable cost. While invasive intracranial pressure monitoring has been available for many years, non-invasive measurement has so far not been accurate enough. Nisonic is developing an software that analyzes ultrasound images of the eye to monitor increased ICP, and that can be integrated into ultrasound devices on the market, enabling widespread use among physicians and other health workers.

AttgeNO is a pharmaceutical company developing treatments for acute life-threatening conditions.